- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07759154
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
A Phase 3b, Multicenter, Open-label, Single-arm Trial to Evaluate the Efficacy and Safety of Orally Administered Centanafadine QD XR Capsules in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Otsuka Call Center
- Phone Number: 844-687-8522
- Email: otsuka-professionalservices@otsuka-us.com
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32607
- Recruiting
- Sarkis Clinical Trials - Gainesville
-
Contact:
- Otsuka Call Center
- Phone Number: 844-687-8522
- Email: Otsuka-ProfessionalServices@otsuka-us.com
-
Principal Investigator:
- Sarkis
-
Jacksonville, Florida, United States, 32256
- Recruiting
- CNS Healthcare - Jacksonville (Clinical Neuroscience Solutions - Jacksonville)
-
Principal Investigator:
- Jones
-
Contact:
- Otsuka Call Center
- Phone Number: 844-687-8522
- Email: Otsuka-ProfessionalServices@otsuka-us.com
-
Maitland, Florida, United States, 32751
- Recruiting
- Accel Research Sites-Maitland
-
Contact:
- Otsuka Call Center
- Phone Number: 844-687-8522
- Email: Otsuka-ProfessionalServices@otsuka-us.com
-
Principal Investigator:
- Marraffino
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70125
- Recruiting
- Nola Research Works
-
Contact:
- Otsuka Call Center
- Phone Number: 844-687-8522
- Email: Otsuka-ProfessionalServices@otsuka-us.com
-
Principal Investigator:
- Hebert
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02132
- Recruiting
- Boston Clinical Trials
-
Contact:
- Otsuka Call Center
- Phone Number: 844-687-8522
- Email: Otsuka-ProfessionalServices@otsuka-us.com
-
Principal Investigator:
- Mezhebovsky
-
Watertown, Massachusetts, United States, 02472
- Recruiting
- Adams Clinical - Watertown
-
Contact:
- Otsuka Call Center
- Phone Number: 844-687-8522
- Email: Otsuka-ProfessionalServices@otsuka-us.com
-
Principal Investigator:
- Rutrick
-
-
Missouri
-
Saint Charles, Missouri, United States, 63304
- Recruiting
- St. Charles Psychiatric Associates/Midwest Research Group
-
Contact:
- Otsuka Call Center
- Phone Number: 844-687-8522
- Email: Otsuka-ProfessionalServices@otsuka-us.com
-
Principal Investigator:
- Mattingly
-
-
Nevada
-
Las Vegas, Nevada, United States, 89128
- Recruiting
- Center for Psychiatry and Behavioral Medicine. Inc.
-
Contact:
- Otsuka Call Center
- Phone Number: 844-687-8522
- Email: Otsuka-ProfessionalServices@otsuka-us.com
-
Principal Investigator:
- Childress
-
-
New Jersey
-
Cherry Hill, New Jersey, United States, 08002
- Recruiting
- Center for Emotional Fitness
-
Contact:
- Otsuka Call Center
- Phone Number: 844-687-8522
- Email: Otsuka-ProfessionalServices@otsuka-us.com
-
Principal Investigator:
- Corcoran
-
-
New York
-
New York, New York, United States, 10128
- Recruiting
- The Medical Research Network, LLC
-
Contact:
- Otsuka Call Center
- Phone Number: 844-687-8522
- Email: Otsuka-ProfessionalServices@otsuka-us.com
-
Principal Investigator:
- Careri
-
-
Ohio
-
Cincinnati, Ohio, United States, 45215
- Recruiting
- Patient Priority Clinical Trials
-
Contact:
- Otsuka Call Center
- Phone Number: 844-687-8522
- Email: Otsuka-ProfessionalServices@otsuka-us.com
-
Principal Investigator:
- Popovitz
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Recruiting
- Summit Research Network
-
Contact:
- Otsuka Call Center
- Phone Number: 844-687-8522
- Email: Otsuka-ProfessionalServices@otsuka-us.com
-
Principal Investigator:
- Essink
-
-
Texas
-
Austin, Texas, United States, 78737
- Recruiting
- Donald J. Garcia, Jr, MD, PA
-
Principal Investigator:
- Garcia
-
Contact:
- Otsuka Call Center
- Phone Number: 844-687-8522
- Email: Otsuka-ProfessionalServices@otsuka-us.com
-
Bellaire, Texas, United States, 77401
- Recruiting
- Houston Clinical Trials LLC
-
Contact:
- Otsuka Call Center
- Phone Number: 844-687-8522
- Email: Otsuka-ProfessionalServices@otsuka-us.com
-
Principal Investigator:
- Katic
-
Houston, Texas, United States, 77089
- Recruiting
- Kaleidoscope Clinical Research
-
Contact:
- Otsuka Call Center
- Phone Number: 844-687-8522
- Email: Otsuka-ProfessionalServices@otsuka-us.com
-
Principal Investigator:
- Higgins
-
-
Washington
-
Everett, Washington, United States, 98201
- Recruiting
- Core Clinical Research
-
Contact:
- Otsuka Call Center
- Phone Number: 844-687-8522
- Email: Otsuka-ProfessionalServices@otsuka-us.com
-
Principal Investigator:
- Knutson
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Primary diagnosis of ADHD per the Adult ADHD Clinical Diagnostic Scale (ACDS).
- Adult ADHD Investigator Symptom Rating Scale (AISRS) total score of ≥ 28 at baseline.
- Symptoms of ED as determined by the WRAADDS-ED subscale score ≥ 7 at baseline.
- CGI-S-ADHD rating ≥ 4 (at least moderate severity) at baseline.
Exclusion Criteria
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for a lifetime diagnosis of bipolar and related disorders, schizophrenia spectrum and other psychotic disorders, borderline and antisocial personality disorders, neurocognitive disorders, autism spectrum disorder, or intellectual disability.
- DSM-5 criteria for a current diagnosis of major depressive disorder, post-traumatic stress disorder, any substance use disorder, untreated/unstable obstructive sleep apnea, eating disorders, or obsessive compulsive disorder.
- Any other current DSM-5 comorbid psychiatric disorder identified by the Mini International Neuropsychiatric Interview (MINI) or any medical condition that, in the judgment of the investigator, could be expected to require treatment with medications prohibited in this trial that cannot be safely discontinued with completion of an appropriate washout, could confound efficacy or safety assessments, or be the primary driver of ED.
- Presence of an unstable or uncontrolled medical condition that, in the opinion of the investigator, could pose a safety risk to the participant or could manifest with psychiatric symptoms (eg, thyroid disease).
- In the clinical opinion of the investigator, the participant has not derived significant therapeutic benefit from 2 or more ADHD therapies of 2 different classes (eg, amphetamine and methylphenidate, or amphetamine and atomoxetine) given with an acceptable dose and duration during adulthood (aged 18 years or older).
- Current use of prohibited psychotropic medications that cannot be discontinued within 7 to 28 days prior to enrollment.
- Any disorder that is the primary focus of treatment other than ADHD.
- Evidence of current substance use disorder or history in the past 12 months.
- History of any prior exposure to centanafadine.
- Participated in other clinical trials involving investigational drugs within 180 days prior to screening or participated in more than 2 interventional clinical trials involving investigational drugs within the past year.
- Have an allergy to the IMP or any component of the IMP.
Note: Other protocol-specified inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Centanafadine XR
Participants will receive centanafadine XR capsule 328.8 milligrams (mg), orally, QD, for 8 weeks. |
Oral capsules
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change From Baseline to Week 8 in the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) Total Score
Time Frame: Baseline up to Week 8
|
Baseline up to Week 8
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change From Baseline to Week 8 in the Wender-Reimherr Adult Attention Deficit Disorder Scale Emotional Dysregulation (WRAADDS-ED) Subscale Score
Time Frame: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Clinical Global Impressions-Severity Scale for Attention-Deficit/Hyperactivity Disorder (CGI-S-ADHD) Score
Time Frame: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) T-score for the Global Executive Composite (GEC) Scale
Time Frame: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the BRIEF-A T-score for the Behavioral Regulation Index (BRI) Scale
Time Frame: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the BRIEF-A T-score for the Metacognition Index (MI) Scale
Time Frame: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Difficulties in Emotion Regulation Scale (DERS) Total Score
Time Frame: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Nonacceptance of Emotional Responses (NONACCEPT) DERS Subscale Score
Time Frame: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Difficulties Engaging in Goal-Directed Behavior (GOALS) DERS Subscale Score
Time Frame: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Impulse Control Difficulties (IMPULSE) DERS Subscale Score
Time Frame: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Lack of Emotional Awareness (AWARE) DERS Subscale Score
Time Frame: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Limited Access to Emotion Regulation Strategies (STRATEGIES) DERS Subscale Score
Time Frame: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Lack of Emotional Clarity (CLARITY) DERS Subscale Score
Time Frame: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Attention-Deficit/Hyperactivity Disorder Symptoms, Executive Function Deficits, and Emotional Dyscontrol as Assessed by the Adult ADHD Self-Report Scale (ASRS) Score
Time Frame: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Number of Participants With Adverse Events
Time Frame: Up to Week 9
|
Up to Week 9
|
|
Number of Participants With Suicidal Ideation or Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Time Frame: Up to Week 9
|
Up to Week 9
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 405-201-00231
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
IPD Sharing Time Frame
Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
IPD Sharing Access Criteria
Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.